ALK and non-small cell lung carcinoma: Patients with ALK-positive NSCLC had a numerically higher rate of ATE (12/155, 7.7%) compared to ALK-negative cases (299/4607, 6.5%); however, ALK-positive NSCLC was not significantly associated with a higher risk for ATE (HR 1.24 [0.62-2.47]) (Table 2).